U.S. FDA grants approval for Lupin’s generic Tolvaptan tablets  


Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for Tolvaptan tablets of different strengths.

It is the exclusive first-to-file for this product and consequently eligible for 180 days of generic drug exclusivity. The product will be manufactured at its Nagpur facility and launched soon, Lupin said on Thursday.

The approved product is bioequivalent to Otsuka Pharmaceutical Company’s Jynarque Tablets 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease.

Tolvaptan tablets had an estimated annual sale of $1,467 million in the U.S. during 2024.

CEO Vinita Gupta said the development marks “a significant entry into the nephrology segment” for the company.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *